A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non Small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD 1/L 1 Inhibitor, EGFR, or ALK Inhibitor
For more information about the trial above please contact the study team:
Principal Investigator, Mariam Alexander, at email@example.com.
Study Coordinator, Alexandra Leitner, at firstname.lastname@example.org, or please call +1 843-792-1507.
Trial opened at the following institutions: Medical University of South Carolina